Antimineralocorticoid

From Wikipedia, the free encyclopedia
  (Redirected from Aldosterone antagonist)
Jump to: navigation, search
Antimineralocorticoid
Drug class
Spironolactone.svg
Spironolactone, the most widely used antimineralocorticoid.
Class identifiers
Synonyms Aldosterone antagonist; Mineralocorticoid antagonist
Use Diuretic; Chronic heart failure; Hypertension; Hyperaldosteronism; Conn's syndrome
Biological target Mineralocorticoid receptor
Chemical class Steroidal; Non-steroidal
In Wikidata

An antimineralocorticoid, MCRA,[1] or an aldosterone antagonist, is a diuretic drug which antagonizes the action of aldosterone at mineralocorticoid receptors. This group of drugs is often used as adjunctive therapy, in combination with other drugs, for the management of chronic heart failure. Spironolactone, the first member of the class, is also used in the management of hyperaldosteronism (including Conn's syndrome) and female hirsutism (due to additional antiandrogen actions). Most antimineralocorticoids, including spironolactone, are steroidal spirolactones. Finerenone is a non-steroidal antimineralocorticoid.

Mechanism of action[edit]

Aldosterone antagonists are, as the name suggests, receptor antagonists at the mineralocorticoid receptor. Antagonism of these receptors inhibits sodium resorption in the collecting duct of the nephron in the kidneys. This interferes with sodium/potassium exchange, reducing urinary potassium excretion and weakly increasing water excretion (diuresis).[2]

In congestive heart failure, they are used in addition to other drugs for additive diuretic effect, which reduces edema and the cardiac workload.

Examples[edit]

Skeletal formulae of aldosterone antagonists.

Members of this class in clinical use include:

Some drugs also have antimineralocorticoid effects secondary to their main mechanism of actions. Examples include progesterone, drospirenone, gestodene, and benidipine.[3]

See also[edit]

References[edit]

  1. ^ The Krause/King-Lewis acronym, developed at Naval Medical Center San Diego, of MCRA was developed during February 2017 to distinguish between MRA for a specific MRI which are both widely recognized medical acronyms as compared to the use of MRA for mineralocorticoid receptor antagonist type medications which is only used as a medical acronym in the cardiology and nephrology word.
  2. ^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.
  3. ^ Kosaka H, Hirayama K, Yoda N, Sasaki K, Kitayama T, Kusaka H, Matsubara M (2010). "The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family". Eur. J. Pharmacol. 635 (1-3): 49–55. doi:10.1016/j.ejphar.2010.03.018. PMID 20307534. 

External links[edit]